6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

HIV Epidemiology & Diagnostic Algorithms in the Caribbean

The Caribbean region historically has the second highest adult HIV prevalence globally after sub-Saharan Africa. Transmission is predominantly heterosexual, although high burdens persist among key vulnerable populations. Universal Prevention of Mother-to-Child Transmission (PMTCT) programs across the region have successfully eliminated congenital HIV transmission in numerous Caribbean territories through maternal universal screening, triple-antiretroviral prophylaxis during pregnancy, scheduled cesarean delivery for elevated viral loads, and infant formula feeding.

Modern Diagnostic Screening Pathway

• 4th-Generation Combination Immunoassay: A laboratory screening option; national Caribbean algorithms also use rapid tests. Follow the applicable validated algorithm rather than assuming one regional sequence. This automated chemiluminescent or enzyme immunoassay detects both HIV-1 and HIV-2 antibodies (IgG and IgM) AND the HIV-1 p24 capsid antigen.
  • Diagnostic Advantage: p24 antigen permits earlier detection than antibody alone. Venous laboratory antigen/antibody tests usually detect infection 18–45 days after exposure, versus 23–90 days for antibody tests. An early negative result may need repeat testing after the applicable window.
• Confirmatory Testing: In the CDC laboratory algorithm, a repeatedly reactive 4th-generation screening test is followed by an HIV-1 / HIV-2 antibody differentiation immunoassay (e.g. Geenius assay). This distinguishes HIV-1 from HIV-2, which is critical because HIV-2 is intrinsically resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and certain protease inhibitors.
• Discrepant or Acute Infection Testing: If the 4th-generation screen is reactive but the differentiation immunoassay is non-reactive or indeterminate, an emergency quantitative HIV-1 RNA PCR viral load is performed. A high viral load (> 100,000 copies/mL) confirms acute primary HIV infection before seroconversion.

---

Natural History, CD4 Progression & Opportunistic Infections

Following primary infection (which manifests in 50% to 70% of individuals as an acute mononucleosis-like retroviral syndrome), HIV enters a prolonged clinical latency phase lasting 8 to 10 years. Progressive viral replication leads to gradual destruction of CD4+ T-helper lymphocytes. Depletion below specific immunological thresholds predisposes the host to characteristic opportunistic infections (OIs) and malignancies.

Stratification of Opportunistic Conditions by CD4 Count

---

Deep Dive: Major Opportunistic Infections

1. Pneumocystis jirovecii Pneumonia (PCP / PJP)

• Pathophysiology & Clinical Course: An atypical unicellular fungus that adheres to type I alveolar pneumocytes. Characterized by an insidious, subacute onset over 2 to 4 weeks with dry non-productive cough, low-grade fever, and progressive exertional breathlessness. A classic diagnostic hallmark is exertional oxygen desaturation out of proportion to physical examination (e.g. resting SpO2 94% dropping rapidly to < 85% upon walking across the room).
• Investigations:
  • CXR: Bilateral symmetrical perihilar ground-glass interstitial infiltrates in a 'bat-wing' distribution. Normal in 10% to 15% of early cases.
  • Serum biomarkers: Elevated lactate dehydrogenase (LDH > 400 U/L) and elevated (1->3)-beta-D-glucan.
  • Definitive diagnosis: Induced sputum with hypertonic saline or bronchoalveolar lavage (BAL) stained with Gomori methenamine silver (GMS) or direct fluorescent antibody (DFA).
• Pharmacotherapy:
  • First-Line: High-dose intravenous or oral Trimethoprim-Sulfamethoxazole (TMP-SMX): Trimethoprim 15 to 20 mg/kg/day plus Sulfamethoxazole 75 to 100 mg/kg/day, divided into 3 or 4 doses daily for a total duration of 21 days.
  • Mandatory Adjunctive Corticosteroids: If arterial blood gas reveals moderate-to-severe hypoxemia—defined as $PaO_2 < 70\text{ mmHg}$ or Alveolar-arterial (A-a) gradient $\ge 35\text{ mmHg}$ on room air—start systemic corticosteroids as soon as possible, ideally within 72 hours of starting PCP therapy; do not delay TMP-SMX while arranging steroids.
  • Steroid Regimen: Oral Prednisone 40 mg BD on days 1–5, 40 mg OD on days 6–10, then 20 mg OD on days 11–21 (or IV methylprednisolone). Steroids prevent fatal acute respiratory failure induced by the inflammatory surge of dying fungal organisms within alveolar spaces.

2. Cryptococcal Meningitis (Cryptococcus neoformans)

• Presentation: Encapsulated budding yeast inhaled into the lungs with subsequent hematogenous dissemination to the meninges. Manifests subacutely over 1 to 3 weeks with progressive global headache, low-grade fevers, malaise, and vomiting. Classical signs of meningeal irritation (nuchal rigidity, Kernig's, Brudzinski's) are absent in over 50% of patients due to profoundly suppressed cell-mediated inflammation.
• Diagnostic Workup:
  • Emergency Lumbar Puncture: Elevated opening pressure (> 200–250 mmH2O); CSF shows lymphocytic pleocytosis (often modest, 20–200 cells/uL), elevated protein, and low glucose.
  • CSF India Ink Stain: Demonstrates round budding yeasts surrounded by a clear halo (refractile polysaccharide capsule) in 70% to 80% of cases.
  • Cryptococcal Antigen (CrAg) Lateral Flow Assay: Rapid, highly sensitive (> 98%) and specific diagnostic test performed on both CSF and peripheral serum.
• Treatment Protocol:
  • Induction Phase (14 Days): Intravenous Amphotericin B deoxycholate 0.7 to 1.0 mg/kg/day PLUS oral Flucytosine 100 mg/kg/day (in 4 divided doses). In resource-constrained Caribbean settings where flucytosine is unavailable, high-dose oral Fluconazole 1200 mg daily is substituted alongside Amphotericin B.
  • Consolidation Phase (8 Weeks): Oral Fluconazole 400 mg to 800 mg daily.
  • Maintenance / Secondary Prophylaxis: Oral Fluconazole 200 mg daily for at least 1 year from antifungal initiation; stop only when asymptomatic with sustained CD4 >= 100 cells/uL and suppressed HIV RNA on effective ART.
  • Management of Intracranial Pressure (ICP): Elevated opening pressure is the primary cause of acute mortality. If opening pressure is > 250 mmH2O, perform serial daily therapeutic lumbar punctures removing 20 to 30 mL of CSF until pressure drops < 200 mmH2O or by 50%. Lumbar drains or ventriculoperitoneal shunts are reserved for refractory cases.

3. Cerebral Toxoplasmosis (Toxoplasma gondii)

• Reactivation of latent encysted intracellular protozoa occurring at CD4 < 100 cells/uL.
• Presents acutely/subacutely with fever, headache, altered mental status, seizures, and focal neurological deficits (hemiparesis, cranial neuropathies).
• Neuroimaging (Contrast CT / MRI): Multiple ring-enhancing lesions with predilection for the basal ganglia, thalamus, and corticomedullary junction, accompanied by surrounding vasogenic edema.
• Differentiation from Primary CNS Lymphoma: Lymphoma is typically solitary, periventricular, strongly associated with Epstein-Barr virus (EBV PCR positive in CSF), and shows subependymal spread.
• Treatment: Oral Pyrimethamine (200 mg loading, then 50–75 mg daily) PLUS Sulfadiazine (1.0–1.5 g 6-hourly) PLUS Folinic acid (Leucovorin 10–25 mg daily) to prevent pyrimethamine-induced bone marrow megaloblastic anemia. Duration: at least 6 weeks.

4. Cytomegalovirus (CMV) Retinitis

• Reactivation of CMV occurring almost exclusively at severe immunodeficiency ($CD4 < 50/\mu\text{L}$).
• Symptoms: Painless progressive visual impairment, floaters, flashing lights (photopsias), and blind spots (scotomas).
• Fundoscopic Appearance: Classic 'pizza-pie' retinopathy (or 'cottage cheese and ketchup'): dense, confluent, yellow-white perivascular retinal infiltrates and necrotizing retinitis surrounded by extensive retinal hemorrhages and vasculitis.
• Treatment: Intravenous Ganciclovir (5 mg/kg 12-hourly for 14 to 21 days) or oral Valganciclovir 900 mg BD for 21 days, followed by maintenance therapy until immune reconstitution occurs.

---

Antiretroviral Therapy (ART) & Timing Principles

Modern First-Line Regimen: The TLD Triad

Across the Caribbean, the World Health Organization (WHO) recommended first-line regimen for adults and adolescents is the fixed-dose combination TLD taken orally once daily:

• T — Tenofovir Disoproxil Fumarate (TDF, 300 mg): Nucleotide Reverse Transcriptase Inhibitor (NRTI). High efficacy; requires baseline and periodic monitoring of serum creatinine and urinalysis due to risks of proximal renal tubulopathy (Fanconi-like syndrome) and bone mineral density loss. (Tenofovir Alafenamide [TAF] is used in renal impairment).
• L — Lamivudine (3TC, 300 mg): Nucleoside Reverse Transcriptase Inhibitor (NRTI). Well tolerated, minimal toxicity; active against Hepatitis B virus.
• D — Dolutegravir (DTG, 50 mg): An INSTI with rapid suppression and a high resistance barrier. With rifampicin, add DTG 50 mg 12 hours after daily TLD; continue the extra dose for 2 weeks after rifampicin ends.

Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS is an exaggerated pathological inflammatory reaction against dead or viable microbial antigens occurring within weeks to months of initiating effective ART, triggered by the rapid restoration of pathogen-specific cell-mediated immune responses. It manifests in two forms:

• Paradoxical IRIS: Worsening of a treated, recognized opportunistic infection despite microbiological cure.
• Unmasking IRIS: Explosive presentation of a previously subclinical, occult infection.

The Timing Dilemma: When to Start ART in Opportunistic Infections

• General Rule for Most OIs (PCP, Bacterial Pneumonia, Diarrheal Illnesses): Initiate ART within 2 weeks of starting OI therapy ('immediate ART'). Delaying ART increases the risk of AIDS progression and mortality.
• CRITICAL EXCEPTION 1: Cryptococcal Meningitis:
  • Generally defer ART initiation for 4 to 6 weeks after starting antifungal induction therapy, until CSF fungal clearance is documented and intracranial pressure is controlled.
  • Rationale: The COAT trial found higher 26-week mortality with ART started at 1–2 weeks than with deferred initiation around 5 weeks. Intracranial inflammatory deterioration is a major concern; early ART should not be used to accelerate recovery from cryptococcal meningitis.
• CRITICAL EXCEPTION 2: Tuberculous Meningitis:
  • ART must be delayed for 4 to 8 weeks after starting antitubercular therapy (HRZE) and high-dose dexamethasone, similarly to prevent fatal cerebral IRIS. (In pulmonary non-CNS TB with CD4 < 50, start ART within 2 weeks; with CD4 >= 50, start within 8 weeks).

---

Hospital Antimicrobial Stewardship Principles

Antimicrobial resistance (AMR) represents an existential threat to healthcare delivery in the Caribbean. Overuse of broad-spectrum antimicrobials fuels the emergence of Multidrug-Resistant Organisms (MDROs), notably Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae (CRE), Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE).

Core Tenets of Clinical Stewardship

1. Diagnostic Stewardship: Obtain appropriate high-volume blood cultures (at least two sets from separate venipuncture sites) and target-site cultures (urine, sputum, pleural fluid, CSF) BEFORE administering antimicrobials, without causing unreasonable delays in patients with septic shock.
2. The 48- to 72-Hour Antimicrobial 'Time-Out': When microbiological culture and susceptibility results return at 48–72 hours, clinicians must reassess therapy:
   • De-escalation: Switch from broad empiric regimens (e.g. piperacillin-tazobactam or meropenem) to the narrowest-spectrum agent directed against the identified isolate (e.g. de-escalating to high-dose ampicillin or ceftriaxone for fully susceptible pneumococcus).
   • Discontinuation: Stop empiric MRSA coverage when cultures, infection site, local epidemiology and clinical response make MRSA unlikely. A negative nasal PCR supports de-escalation in appropriate pneumonia settings; it does not exclude every MRSA infection. Stop antibiotics when an infectious cause is ruled out.
3. Early Intravenous-to-Oral (IV-to-PO) Switch: Review at 48–72 hours and switch when the patient is improving, GI absorption is adequate and an effective oral regimen suits the infection. High-bioavailability options include ciprofloxacin, linezolid, fluconazole, metronidazole and doxycycline. CNS, endovascular and other deep infections require syndrome-specific plans.
4. Therapeutic Drug Monitoring (TDM) & Renal Dosing: Calculate Cockcroft-Gault creatinine clearance daily for renally excreted toxic drugs (vancomycin, aminoglycosides, colistin). For serious MRSA infections, use AUC-guided vancomycin dosing (AUC24 400–600 mg·h/L, assuming MIC 1 mg/L) and monitor renal function; trough-only targeting of 15–20 mcg/mL is no longer recommended because of nephrotoxicity.